This technology relates to the generation and use of an antibody that recognizes the S1459 phosphorylated site of the GRIN2A gene, which encodes the GluN2A subunit of the NMDA receptor. This gene is widely accepted as an epilepsy-causative gene and has been implicated in autism spectrum disorder (ASD). The S1459 phosphorylation site was selected based on an identified mutation in an epilepsy patient. This antibody can be used to specifically visualize the localization of the phosphorylated version of the GRIN2A protein product in the brain.
This GRIN2A antibody could potentially be used to visualize phosphorylation of this site in the brain.
There are no other antibodies on the market that detect this specific phosphorylation site of the GRIN2A gene, GluN2A-S1459.